Growth Momentum Revenue growth driven by DAYBUE sales, with Q2 2026 net sales of $125 million and a 30% year-over-year increase. This signals strong market adoption and potential for upselling additional indications or expansion therapies within neurodevelopmental and neurodegenerative indications.

Strategic Partnerships Significant emphasis on DAYBU trofinetide in Europe and ongoing collaboration potential with regional distributors and healthcare providers. Leverage the DAYBUE EU development to create co-promotion or licensing deals to accelerate market access in new geographies.

Expanded Indications Neuren is advancing NNZ-2591 for hypoxic ischemic encephalopathy and pursuing Rett syndrome with DAYBUE STIX, highlighting a pipeline approach across acute brain injury and pediatric neurodevelopmental disorders. Target opportunities include neurology centers, NICUs, and pediatric hospitals seeking novel therapies and companion diagnostics.

FDA Milestones Multiple Fast Track designations for NNZ-2591 and ongoing FDA engagement underscore regulatory momentum. Use these milestones to position partner-led or independent commercialization strategies, while engaging payers on value-based access and accelerated approval timelines.

Financial Signals Royalty-driven revenue model with broad milestones suggests a scalable monetization path. Potential sales opportunities include negotiating milestone-based upfronts, enhanced royalty structures, and regional partnerships tied to performance milestones aligned with registerable clinical outcomes.